GMAB vs. TEVA, ALNY, BGNE, BMRN, VTRS, SRPT, UTHR, RDY, CTLT, and ROIV
Should you be buying Genmab A/S stock or one of its competitors? The main competitors of Genmab A/S include Teva Pharmaceutical Industries (TEVA), Alnylam Pharmaceuticals (ALNY), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), Sarepta Therapeutics (SRPT), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical preparations" industry.
Teva Pharmaceutical Industries (NYSE:TEVA) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, community ranking, dividends, analyst recommendations, institutional ownership, earnings and risk.
Teva Pharmaceutical Industries currently has a consensus target price of $14.22, suggesting a potential downside of 12.69%. Genmab A/S has a consensus target price of $48.50, suggesting a potential upside of 61.77%. Given Teva Pharmaceutical Industries' higher possible upside, analysts clearly believe Genmab A/S is more favorable than Teva Pharmaceutical Industries.
Genmab A/S has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.
In the previous week, Teva Pharmaceutical Industries had 15 more articles in the media than Genmab A/S. MarketBeat recorded 18 mentions for Teva Pharmaceutical Industries and 3 mentions for Genmab A/S. Teva Pharmaceutical Industries' average media sentiment score of 0.87 beat Genmab A/S's score of 0.30 indicating that Genmab A/S is being referred to more favorably in the news media.
Genmab A/S has a net margin of 30.74% compared to Genmab A/S's net margin of -2.88%. Genmab A/S's return on equity of 37.33% beat Teva Pharmaceutical Industries' return on equity.
Teva Pharmaceutical Industries received 1169 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 67.58% of users gave Teva Pharmaceutical Industries an outperform vote while only 60.68% of users gave Genmab A/S an outperform vote.
Teva Pharmaceutical Industries has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.
54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Genmab A/S beats Teva Pharmaceutical Industries on 10 of the 18 factors compared between the two stocks.
Get Genmab A/S News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genmab A/S Competitors List
Related Companies and Tools
